Canaccord raises TransMedics stock price target on strong Q3 results
Canaccord raised its price target on TransMedics (TMDX) to $120 from $95, maintaining a Buy rating after strong Q3 2026 results. Revenue grew 41% YoY to $203M, exceeding estimates. The company raised its full-year guidance to $764M-$774M and plans European expansion in 2027.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh, material data that can move the stock.
Market read
Earnings surprise and upgraded guidance are likely to drive short‑term buying interest.
What to watch
Potential regulatory delays for FDA clearance could temper upside.
Background
TransMedics reported Q3 2026 results with revenue up 41% YoY and raised full‑year revenue guidance.
Ticker impact
Canaccord raised its price target to $120 and highlighted TransMedics' Q3 revenue beat and raised full-year guidance.
upside pressure as the market prices in higher earnings and guidance
The earnings beat and guidance raise are fresh, material information for a mid‑cap biotech.
Market effects
Boosts sentiment for organ‑preservation and transplant‑technology sector.
Positive for US biotech listings, limited broader market effect.
Modest; primarily impacts investors focused on US biotech.
Counterpoint
If the guidance is overly optimistic, the stock may face disappointment on later quarters.
Key entities
- companyTransMedics Group
US‑listed biotech focused on organ preservation.
- analystCanaccord Genuity
Raised price target and issued a Buy rating.
